Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.20 USD
Change Today 0.00 / 0.00%
Volume 0.0
CBIA On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 08/17/15 All times are local (Market data is delayed by at least 15 minutes).

canopus biopharma inc (CBIA) Snapshot

Open
$0.25
Previous Close
$0.20
Day High
$0.25
Day Low
$0.20
52 Week High
12/22/14 - $0.75
52 Week Low
07/27/15 - $0.20
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CANOPUS BIOPHARMA INC (CBIA)

Related News

No related news articles were found.

canopus biopharma inc (CBIA) Related Businessweek News

No Related Businessweek News Found

canopus biopharma inc (CBIA) Details

Canopus BioPharma Incorporated, a pharmaceutical research company, provides pharmaceutical products and assay methods to patients suffering from infectious, cancer, and addiction diseases. It also provides antivirals, radiation protection products, oncology products, bio-barcode assays, camelidae blood products, and neutraceutricals. The company was founded in 1996 as Canopus Corporation and changed its name in 2007. Canopus BioPharma Incorporated is based in Santa Monica, California.

canopus biopharma inc (CBIA) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

canopus biopharma inc (CBIA) Key Developments

Canopus BioPharma Inc. Announces Positive Results from an In-Vitro Live Ebola Virus Study

Canopus BioPharma Inc. announced that it has completed crucial research in confirming efficacy of a prescription drug: CB008 for Ebola Virus inhibition. Laboratories at the Texas Biomedical Research Institute in San Antonio Texas have demonstrated complete in-vitro inhibition of the live Ebola Virus strain Zaire at concentrations of CB008 that are achievable by oral administration. CB008 is only one of a family of prescription drugs which has been demonstrated by Canopus BioPharma to have potential in preventing Hemorrhagic syndrome and inhibiting Ebola Viral replication. CB008 is an in-house codename for a well-established prescription drug first approved by the FDA in the early 1980's for other medical indications. CB008 is an effective, safe treatment for Ebola Virus. Canopus BioPharma has signed a confidential agreement with a major pharmaceutical company who are reviewing the results and the possibility of expediting an Ebola non-human primate study. Following this, CB008 can progress to a human Ebola patient clinical trial in West Africa.

Canopus BioPharma Inc. Announces Results from Compassionate Study in Hepatitis C patients in China

Canopus BioPharma Inc. announced topline results from a Compassionate Clinical Trial in China, evaluating the twice daily oral administration of Mogroside IV (Mogrovir(TM)). Mogrovir(TM) is a Toll-like receptor agonist and stimulator of the patient's immune system. Mogrovir(TM) was administered orally in combination with Ribavirn (RBV), for the treatment of Genotype 1, treatment naive Hepatitis C (HCV) patients. The study showed a statistically significant result regarding the improvement of both liver function and increased blood platelet counts. A selection of patients in the trial also showed a statistically significant reduction in HCV viral-load levels, in the three month follow up period post-therapy. HCV Viral-load in these specific patients were approaching zero after a period of 180 days (90 days Mogrovir(TM) Treatment and 90 days follow-up). This fact confirmed the immune activation effects which are expected from the immune activation characteristics of Mogrovir(TM). Twenty eight patients were enrolled in the Canopus BioPharma study and all patients completed the study, without any toxicity or negative side-effects being documented. Compared to baseline, significant improvements were observed for patients in malaise, anorexia, food intake, abdominal distension and sleep at day 90 of the study. Canopus BioPharma is currently co-ordinating with study centres in Europe and the USA to duplicate the results observed from this Chinese study. Since Hepatitis C and the Dengue Virus are both members of the Flavivirus family, Canopus BioPharma has initiated discussions in Singapore and Thailand with the intention of commencing patient studies with Mogrovir(TM) alone for the treatment of Dengue viral infections in patients.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBIA:US $0.20 USD 0.00

CBIA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CBIA.
View Industry Companies
 

Industry Analysis

CBIA

Industry Average

Valuation CBIA Industry Range
No financial data is available for CBIA.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CANOPUS BIOPHARMA INC, please visit www.canopusbiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.